Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Open Access
- 25 May 2018
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (7) , 867-878
Abstract
The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs).Keywords
Funding Information
- Novartis Pharmaceuticals UK Limited
This publication has 22 references indexed in Scilit:
- Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritisBMC Musculoskeletal Disorders, 2014
- The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologicsRheumatology, 2013
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseAnnals of the Rheumatic Diseases, 2013
- Golimumab in psoriatic arthritis: One‐year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo‐controlled trialArthritis & Rheumatism, 2012
- Adverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database of Systematic Reviews, 2011
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trialJournal of Dermatological Science, 2010
- Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trialBMJ, 2010
- Psoriatic arthritis: epidemiology, clinical features, course, and outcomeAnnals of the Rheumatic Diseases, 2005
- Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of deathArthritis & Rheumatism, 1997